~~<i id='E3C16E6FFD'><strike id='E3C16E6FFD'><tt id='E3C16E6FFD'><pre id='E3C16E6FFD'></pre></tt></strike></i>~~

Home» leisure time» focus

focus

author：leisure time 2025-09-28 04:55:17 Page View：6

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What the airline industry can learn from medicine
Next article： Novavax promises a turnaround & Lilly roils the obesity market

leisure time

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Lawsuit alleges UnitedHealth Group unit illegally denied claims

JimMone/APTheU.S.DepartmentofLaborclaimsinanewlawsuitthataUnitedHealthGroupunitillegallyrejectedemer

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

What the US credit downgrade means for the economy, your finances

1:44TheU.S.CapitolBuildingisshownonAug.1,2023inWashington.AnnaMoneymaker/GettyImagesAratingagencydow

WSS

focus

focus

explore

leisure time

What the US credit downgrade means for the economy, your finances